SAN DIEGO — Older men with MS who used androgen-modifying treatments experienced last disease activity at a later age compared with women and men who refrained from these treatments, according to a poster at ACTRIMS 2023.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.